| Ytd | -11.67% | |
| 1y | 71.37% |
| Open | 539.67 | Prev Close | 536.95 | Low | 512.75 | High | 542.97 | Mkt Cap | 11.86B |
| Vol | 303.74K | Avg Vol | 328.33K | EPS | -13.48 | P/E | N/A | Forward P/E | 41.55 |
| Beta | -1.06 | Short Ratio | 14.11 | Inst. Own | 106.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 508.68 | 200-d Avg | 496.57 | 1yr Est | 678.71 |
/PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) y su filial Ribocure Pharmaceuticals A
SUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (
B of A Securities analyst Alexandria Hammond maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) wit